Pro Medicus Ltd
PME: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| %< | LOCK|JLQW | LOCK|c^F$^m |
Pro Medicus Earnings: Margins Improve but Key Academic Hospital Market Is Limited
Pro Medicus’ fiscal 2025 EBIT grew 40%, with revenue up 32% on contract wins and EBIT margin expanding 450 basis points to 74%. Revenue from new contracts is outstripping cost growth, with new staff for research and development making up most of the year’s increase in costs.
